Huaigeng Xu, MD, PhD
Postdoctoral Scholar
Urology
School of Medicine
Huaigeng Xu was born in China and grew up in Japan.
Show full bio (110 words) Hide full bio
He obtained his MD and PhD in Japan and recently started working at UCSF from March 2020.
During his PhD, he generated low immunogenicity iPS cells by disrupting HLA genes via CRISPR-Cas9 based genome-editing (Xu et al, Cell Stem Cell, 2019). During this work, he learned iPS cell culture and differentiation to blood cells, CRISPR-Cas9 genome editing, immunology (e.g. T cells, NK cells and immune rejection) and basic mouse experiments.
His personal interest is aging, and his ultimate goal in the future is to solve age-related health problems and manage his longevity. He speaks both Japanese and Chinese, and he is willing to interact with a lot of people.
Awards
Show all (5) Hide
- Inoue Research Award for Young Scientists, Inoue Foundation for Science, 2020
- Best Poster Presentation Award, CiRA 2019 International Symposium, 2019
- CiRA Encouragement Award, CiRA, Kyoto University, 2019
- 2nd Best Oral Presentation Award, 2018 CiRA Retreat, 2018
- Best Poster Presentation Award, 2017 CiRA Retreat, 2017
Education & Training
Show all (3) Hide
- PhD Medicine CiRA, Kyoto University 03/2019
- Residency Tsuruga Municipal Hospital 03/2015
- MD Medicine Osaka Medical College 03/2013
Interests
Show all (8) Hide
- Exosomal PD-L1
- Immunology
- Transplant Rejection
- Genome editing
- APCs
- HLA
- Aging
- Senescence
Websites
Show all (1) Hide
- SlideShare (slideshare.net)
Publications (12)
Top publication keywords:
Homologous Recombinationbeta 2-MicroglobulinExonsHLA AntigensDNA, Single-StrandedOligodeoxyribonucleotidesInduced Pluripotent Stem CellsReceptors, VirusGene EditingElectroporationPluripotent Stem CellsRibonucleoproteinsCRISPR-Cas SystemsHistocompatibilityCRISPR-Associated Proteins
-
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Nature biomedical engineering 2022 Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S -
Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.
Molecular therapy. Methods & clinical development 2022 Kitano Y, Nishimura S, Kato TM, Ueda A, Takigawa K, Umekage M, Nomura M, Kawakami A, Ogawa H, Xu H, Hotta A, Takasu N, Tsukahara M -
Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells.
STAR protocols 2021 Xu H, Kita Y, Bang U, Gee P, Hotta A -
Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells.
Nature biomedical engineering 2021 Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T, Ito R, Goto M, Takahashi R, Uemura Y, Hotta A, Kaneko S -
Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.
Stem cell reports 2021 Kagita A, Lung MSY, Xu H, Kita Y, Sasakawa N, Iguchi T, Ono M, Wang XH, Gee P, Hotta A
Show all (7 more) Hide
-
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.
Nature communications 2020 Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, … -
iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.
Stem cell reports 2019 Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H, Matsumoto T, Fujio K, Manz MG, Hotta A, Takizawa H, Eto K, Sugimoto N -
CRISPR-Cas3 induces broad and unidirectional genome editing in human cells.
Nature communications 2019 Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, Xu H, Sasakawa N, Naito Y, Nakada S, Yamamoto T, Sano S, Hotta A, Takeda J, Mashimo T -
Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
Cell stem cell 2019 Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A -
Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles.
Biochemical and biophysical research communications 2018 Zhitnyuk Y, Gee P, Lung MSY, Sasakawa N, Xu H, Saito H, Hotta A -
Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells.
Scientific reports 2018 Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A -
Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.
Stem cells international 2017 Gee P, Xu H, Hotta A